The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint

• Main Authors: Linus Jönsson (Author), Anders Wimo (Author), Ron Handels (Author), Gunilla Johansson (Author), Mercè Boada (Author), Sebastiaan Engelborghs (Author), Lutz Frölich (Author), Frank Jessen (Author), Patrick Gavin Kehoe (Author), Milica Kramberger (Author), Alexandre de Mendonςa (Author), Pierre Jean Ousset (Author), Nikolaos Scarmeas (Author), Pieter Jelle Visser (Author), Gunhild Waldemar (Author), Bengt Winblad (Author)
• Format: Book
• Published: Elsevier, 2023-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Lecanemab, an anti-amyloid antibody with effects on biomarker and clinical endpoints in early Alzheimer's Disease (AD), was granted accelerated approval by the FDA in 2023 and regulatory review in Europe is ongoing. We estimate the population potentially eligible for treatment with lec...